Prf Technologies revenue and profit flow
Fiscal 2025, year ended Dec 31, 2025 · 20-F filed with the SEC
Prf Technologies brought in $17K of revenue in fiscal 2025. It made an operating loss of $5.12M and a net loss of $5.02M.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Fiscal 2025, year ended Dec 31, 2025 · 20-F filed with the SEC
Prf Technologies brought in $17K of revenue in fiscal 2025. It made an operating loss of $5.12M and a net loss of $5.02M.
| In US dollars | FY2025 |
|---|---|
| Revenue | $17K |
| Growth | — |
| Cost of revenue | — |
| Gross profit | — |
| Gross margin | — |
| Research and development | $1.14M |
| Sales, general and admin | $1.4M |
| Other operating costs | $2.6M |
| Operating income | −$5.12M |
| Operating margin | -30129.4% |
| Interest expense | — |
| Pre-tax income | −$5.01M |
| Income tax | $8K |
| Effective tax rate | — |
| Net income | −$5.02M |
| Net margin | -29541.2% |
“—” means the company did not tag that line that year in the standard US taxonomy, not zero. Banks and insurers report no gross or operating profit. “Sales, general and admin” adds sales and marketing to general and administrative when the company reports them apart. Other operating costs are what is left between gross and operating profit after the lines the company tagged.
Twenty years of cash flow, buybacks and debt: Prf Technologies financial history. Margins and valuation next to its industry: Prf Technologies vs its peers. The latest quarter, insider trades and fund moves: Prf Technologies (PRFX) on OQRO.
Prf Technologies: Pharmaceutical Preparations company based in Tel Aviv, Israel. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026. It is listed in the Pharmaceutical Preparations industry, Health Care sector.
$17K, in the fiscal year that ended Dec 31, 2025, as reported in its 20-F.
$1.14M in fiscal 2025, or 6682.4% of revenue.
A net loss of $5.02M, after an operating loss of $5.12M and income tax of $8K.
The SEC’s companyfacts data: the full-year figures Prf Technologies tagged in XBRL in its annual reports (10-K, 20-F or 40-F). When a later report restates a year, the later figure is used. Revenue, cost of revenue, gross profit, research and development, selling, general and administrative costs, operating income, pre-tax income, income tax and net income are the company’s own lines.
Lines marked * are differences: other operating costs are gross profit minus operating profit minus the cost lines the company tagged; “interest and other” is operating profit minus tax minus net income, so it holds interest, investment gains and losses, minority stakes and discontinued operations together. When the tagged cost of revenue and gross profit disagree, the company’s gross profit is kept. The segment, product and region splits come from the dimensioned revenue facts of the latest annual report’s XBRL instance: a split is shown only when its parts add up to the company’s total revenue within 1%, and labels are the company’s own. This page describes the past and is not investment advice. No language model wrote it.